xRead Articles - October 2022

Nighttime cough frequency (coughs/hr) CQLQ

None 2 weeks CSI LCQ

Time (days) to maximal effect GerdQ

Capsaicin cough challenge

Laryngeal EMG

Videostroboscopy

Cough global rating of change RSI

GFI

Cough severity VAS

Secondary outcome measure(s)

Cough severity VAS

Daily cough symptom diary LCQ

None 3 weeks Subjective cough reduction

None 8 weeks Cough symptom score

improvement (yes or no)

Hong et al (2019) Anyang, Korea Prospective case series 33; 33 (10/23) 47 Inhaled corticosteroid : fl uticasone 250 μ g/ inhalation BID or None 2 weeks Degree of persistent cough compared to baseline

Prospective case series 13; 13 (2/11) 60.1 NK-1 inhibitor : orvepitant 30 mg daily None 4 weeks Daytime cough frequency (coughs/hr)

12; 10 (6/6) 58 Neuromodulator : pregabalin None 4 weeks Subjective rating of chief complaint

improvement (yes or no)

16 days Daytime cough frequency

(coughs/hr)

None 4 weeks Subjective

6 months LCQ

Primary outcome measure

1 or more months Subjective

Treatment

duration

PPI/antihistamine and lifestyle modi fi cations (3)

Re fl ux regimen:

gabapentin maximum 1800 mg daily (19)

Neuromodulator

Comparator

intervention (n patients) Placebo

oral tablet BID

Prospective case series 12; 12 (8/4) 52 Tricyclic antidepressant : Xu et al (2013) Shanghai, China Prospective case series 16; 12 (9/7) 47.8 Neuromodulator + PPI :

11; 11 (1/10) E: 67.3 C: 54.3 Tricyclic antidepressant :

28; 28 (12/16) 61 Tricyclic antidepressant :

budesonide 400 μ g/ inhalation BID

amitriptyline or nortriptyline maximum 50 – 60 mg daily (9)

16; 16 (6/10) 63 Opioid analgesic : tramadol

20; 20 (8/12) 53 Neuromodulator : gabapentin

maximum up to 50 mg daily neuromodulator : gabapentin or

P2X3 inhibitor : gefapixant Study 1:

TABLE I.

Continued

+ omeprazole 20 mg BID 50 mg TID PRN

amitriptyline 10 mg qHS

baclofen 20 mg TID

amitriptyline 25 mg qHS,

maximum 900 mg daily or

carbamazepine 100 mg TID (if gabapentin intolerable)

pregabalin, dose NR (if

amitriptyline intolerable) (8) started at 75 mg BID,

maximum 150 mg BID

50 mg/100 mg/

150 mg/200 mg BID, dose escalated every 4 days Study 2:

7.5 mg/15 mg/30 mg/50 mg BID, dose escalated every 4 days

Experimental intervention (n patients)

Average

age in

years

Study 1: 63.2

Study 2: 60.2

Study 2: 30; 29 (10/49)

# Patients enrolled;

completed therapy (males/females)

series

cohort

series

case series

cohort

Study

design

Crossover RCT Study 1: 29; 27

Lee et al (2005) New York, NY USA Prospective case Bastian et al (2006) Downers Grove, IL, USA

Dion et al (2017) New York, NY USA Prospective case Smith et al (2020) Manchester, England, UK

Smith et al (2020) Manchester, England, UK

Norris et al (2010) Jackson, MS, USA Retrospective

Halum et al (2009) Indianapolis, IN, USA Retrospective

Bowen et al (2018) Cleveland, OH, USA Prospective

trial number (year) Location

Author or clinical

Laryngoscope 132: January 2022

Wamkpah et al.: Multimodal Treatments for Neurogenic Cough

112